Patents by Inventor Verena Adamer

Verena Adamer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200385401
    Abstract: The present invention relates to crystalline forms of cabotegravir sodium and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising one of said crystalline forms of cabotegravir sodium, preferably in a predetermined and/or effective amount, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment and/or prophylaxis of viral infections such as HIV infections.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 10, 2020
    Applicant: Sandoz AG
    Inventors: Verena Adamer, Andrea Thaler
  • Patent number: 10265326
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: April 23, 2019
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Patent number: 10206880
    Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: February 19, 2019
    Assignee: Sandoz AG
    Inventors: Verena Adamer, Andreas Krekeler, Michael Sedlmayr
  • Publication number: 20180193351
    Abstract: The present invention relates to crystalline form C of avibactam sodium and to a process for its preparation. The invention also concerns a pharmaceutical composition comprising form C and one or more antibacterial agents, wherein at least one antibacterial agent is a beta-lactam antibiotic. The pharmaceutical composition of the present invention can be used as medicament, in particular for treatment and/or prevention of bacterial infections.
    Type: Application
    Filed: August 9, 2016
    Publication date: July 12, 2018
    Applicant: Sandoz AG
    Inventors: Andreas Hotter, Verena Adamer, Hannes Lengauer
  • Patent number: 9732053
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: August 15, 2017
    Assignee: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas Hotter, Robert Ziegert-Knepper, Verena Adamer, Arthur Pichler
  • Publication number: 20170027873
    Abstract: A solid dispersion comprising suvorexant or a salt thereof in amorphous form and at least one pharmaceutically acceptable matrix compound, wherein the matrix compound is (i) a polymer and wherein the solid dispersion contains the suvorexant or salt thereof in an 5 amount of at least 50 weight-% based on the combined weight of the suvorexant or salt thereof and the at least one matrix compound, or (ii) a silicon-based inorganic adsorbent.
    Type: Application
    Filed: April 17, 2015
    Publication date: February 2, 2017
    Applicant: Sandoz AG
    Inventors: Verena Adamer, Andreas Krekeler, Michael Sedlmayr
  • Publication number: 20160289202
    Abstract: The present invention relates to 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate in crystalline form and to methods for the preparation thereof. In addition the present invention relates to solid pharmaceutical compositions for oral administration comprising an effective amount of the crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate. Moreover, the present invention relates to the use of crystalline 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine acetate for the preparation of pharmaceutical compositions.
    Type: Application
    Filed: June 30, 2014
    Publication date: October 6, 2016
    Applicant: LEK PHARMACEUTICALS D.D.
    Inventors: Andreas HOTTER, Robert ZIEGERT, Verena ADAMER, Arthur PICHLER
  • Patent number: 8946441
    Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
    Type: Grant
    Filed: June 24, 2011
    Date of Patent: February 3, 2015
    Assignee: Sandoz AG
    Inventors: Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes
  • Publication number: 20130137734
    Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions camprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
    Type: Application
    Filed: June 24, 2011
    Publication date: May 30, 2013
    Applicant: SANDOZ AG
    Inventors: Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes